Galapagos To Present Phase 1 Data On FFA2 Antagonist GLPG0974 At UEG Week In Berlin

MECHELEN, Belgium, Oct. 16, 2013 (GLOBE NEWSWIRE) --
Galapagos  NV (Euronext:  GLPG) announcedtoday that the Company will present in vitro and Phase 1 data showing potent andselective inhibition of FFA2 by GLPG0974 at the United European GastroenterologyWeek,  taking place  from 12 to  16 October 2013 in  Berlin, Germany.  "The FFA2antagonist  GLPG0974: Opportunity to  treat neutrophil-driven inflammation" willbe  presented on 16 October from 9 am to 2 pm CET and has been granted Poster ofExcellence  designation from the  UEG Week Scientific  Committee.  The poster isalso now available online at  (free fatty acid receptor  2) has been shown to  play a role in neutrophilmigration.   Over-activity  of  neutrophils  is  a  cause  of  tissue  damage inillnesses such as inflammatory bowel disease.  In the EUG Week poster, Galapagosprovides  in  vitro  pharmacology  supporting  that  GLPG0974  is  a  potent andselective   antagonist   of   FFA2,   and  favorable  Phase  I  pharmacokinetic,pharmacodynamic, and safety data with GLPG0974.About candidate drug GLPG0974GLPG0974 is an orally available small molecule that reduces migration ofneutrophils, one of the critical cell types in inflammatory processes, by potentinhibition of FFA2 (also known as GPR43). Over-activity of neutrophils is acause of tissue damage in illnesses such as inflammatory bowel disease.  Areduction of neutrophil activation and migration by inhibition of FFA2 mayprovide for a novel anti-inflammatory treatment approach.  By inhibiting FFA2,GLPG0974 prevents free fatty acid-induced activation and migration ofneutrophils towards an inflammatory site, such as in the gut of patients withinflammatory bowel disease.  GLPG0974 is the first inhibitor of FFA2 to beevaluated clinically.  Galapagos expects to report results of the Proof ofConcept study in ulcerative colitis in early 2014.About GalapagosGalapagos  (Euronext: GLPG; OTC: GLPYY) is specialized in novel modes-of-action,with  a large pipeline of  five Phase 2 (two led  by GSK), one Phase 1, six pre-clinical,  and  20 discovery  small-molecule  and  antibody  programs  in cysticfibrosis, inflammation, antibiotics, metabolic disease, and other indications.AbbVie  and Galapagos signed an agreement  in CF where they work collaborativelyto  develop and commercialize oral drugs that  address two mutations in the CFTRgene,  the G551D and F508del mutation.  In the field of inflammation, AbbVie andGalapagos   signed   a  worldwide  license  agreement  whereby  AbbVie  will  beresponsible  for  further  development  and  commercialization of GLPG0634 afterPhase  2B.  GLPG0634 is an orally-available, selective inhibitor of JAK1 for thetreatment  of rheumatoid arthritis and  potentially other inflammatory diseases,currently  in  Phase  2B studies  in  RA  and  about to enter Phase 2 studies inCrohn's  disease.  Galapagos has another selective  JAK1 inhibitor in Phase 2 inlupus   and   psoriasis,   GSK2586184   (formerly   GLPG0778,   in-licensed   byGlaxoSmithKline  in  2012).  GLPG0974  is  the  first  inhibitor  of  FFA2 to beevaluated  clinically for the treatment  of IBD; this program  is currently in aProof-of-Concept  Phase  2 study.   GLPG1205  is  a first-in-class molecule thattargets  inflammatory disorders  and is  currently in  a First-in-Human Phase 1study.The  Galapagos Group, including fee-for-service  companies BioFocus, Argenta andFidelta,  has around  800 employees and  operates facilities  in five countries,with   global  headquarters  in  Mechelen,  Belgium.   Further  information  at:www.glpg.comContactElizabeth Goodwin, Director Investor RelationsTel: +31 6 2291 6240ir@glpg.comGalapagos forward-looking statementsThis release may contain forward-looking statements, including, withoutlimitation, statements containing the words "believes," "anticipates,""expects," "intends," "plans," "seeks," "estimates," "may," "will," "could,""stands to," and "continues," as well as similar expressions. Such forward-looking statements may involve known and unknown risks, uncertainties and otherfactors which might cause the actual results, financial condition, performanceor achievements of Galapagos, or industry results, to be materially differentfrom any historic or future results, financial conditions, performance orachievements expressed or implied by such forward-looking statements. Giventhese uncertainties, the reader is advised not to place any undue reliance onsuch forward-looking statements. These forward-looking statements speak only asof the date of publication of this document. Galapagos expressly disclaims anyobligation to update any such forward-looking statements in this document toreflect any change in its expectations with regard thereto or any change inevents, conditions or circumstances on which any such statement is based, unlessrequired by law or regulation.Galapagos to present Phase 1 data on GLPG0974:[HUG#1735886]